Durable MRD‐Negative Remission With Blinatumomab and Venetoclax in Heavily Pretreated Relapsed/Refractory Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia
eJHaem · 2026-06 · 7 (3)
DOI: 10.1002/jha2.70317 ↗Kurz gefasst
Fachartikel in der Zeitschrift eJHaem, online erschienen am 28.05.2026. Verfasst von Mohammad Shahzaib Qadir und 2 weiteren Autor:innen. Beteiligte Einrichtung: Medical College Aga Khan University Karachi Pakistan. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Tyrosine kinase inhibitors (TKIs) are standard therapy for Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukemia (ALL); however, relapsed or refractory disease remains challenging due to resistance driven by ABL kinase domain mutations.
Methods
We report the case of a heavily pretreated patient with relapsed/refractory Ph+ ALL treated with blinatumomab and venetoclax without concurrent TKI therapy.
Results
The patient achieved complete remission and remains in a deep, durable remission exceeding 1 year.
Conclusion
This case highlights a potential kinase‐independent, TKI‐free strategy for relapsed/refractory Ph+ ALL, warranting further investigation. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission
Autor:innen und Institutionen
- Medical College Aga Khan University Karachi Pakistan.
- Department of Medicine University of Alabama at Birmingham Birmingham Alabama USA.
- Division of Hematology/Oncology Department of Medicine University of Alabama at Birmingham Birmingham Alabama USA.
Zitieren
APA
Qadir, M. S., Farooq, S., & Jamy, O. (2026). Durable MRD‐Negative Remission With Blinatumomab and Venetoclax in Heavily Pretreated Relapsed/Refractory Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia. eJHaem, 7(3). https://doi.org/10.1002/jha2.70317
Vancouver
Qadir MS, Farooq S, Jamy O. Durable MRD‐Negative Remission With Blinatumomab and Venetoclax in Heavily Pretreated Relapsed/Refractory Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia. eJHaem. 2026;7(3). doi:10.1002/jha2.70317
BibTeX
@article{Qadir2026,
author = {Qadir, Mohammad Shahzaib and Farooq, Shereen and Jamy, Omer},
title = {Durable MRD‐Negative Remission With Blinatumomab and Venetoclax in Heavily Pretreated Relapsed/Refractory Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia},
journal = {eJHaem},
year = {2026},
volume = {7},
number = {3},
doi = {10.1002/jha2.70317}
}
EUVIMED